Snipr Biome to send first candidate to clinic

CRISPR company Snipr Biome has an exciting year ahead, as the US Food and Drug Administration (FDA) has approved the company's application to initiate a phase I clinical trial with the company's first development candidate, SNIPR001, which is designed to target E. coli in the gut, a press release announces.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Snipr Biome to collaborate with US cancer hospital
For subscribers